MedTrace Logo

Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial

NCT07775482 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-08-20

No results posted yet for this study

Summary

This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI). This study will explore whether finerenone can mitigate the risk of transitioning to chronic kidney disease following a moderate to severe AKI. Participants will be randomly assigned to receive either finerenone or a placebo, once daily for up to 45 days, in addition to their standard care. The study will monitor for side effects such as serum potassium levels and blood pressure, and will assess whether the drug helps prevent AKI from progressing to chronic kidney disease. This is a pilot feasibility study involving approximately 72 participants across 4-5 sites in Quebec and Ontario.

Conditions

Interventions

DRUG

Finerenone (BAY94-8862 ) 10 mg

Finerenone 10mg, oral capsule, administered once daily for up to 45 days

DRUG

Placebo

Matching placebo capsule, identical in appearance to finerenone 10mg, administered orally once daily for up to 45 days

Sponsors & Collaborators

  • Jean-Maxime Côté

    lead OTHER

Principal Investigators

  • Jean-Maxime Côté, MD, MSc., FRCPC · Centre hospitalier de l'Université de Montréal (CHUM)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-31
Primary Completion
2029-01-31
Completion
2030-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07775482 on ClinicalTrials.gov